



INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH



MICROSPHERES: REVIEW

Kaveri Wagh^{*}, Krutanjali Rajesh Nikumbh, Nidhi Ashish Parikh, Dheeraj Raghunath Chavan, Shailesh Ram Kokani, Ranjana Prakash Guroda, Ansari Sadiya Bano Habeeburrahman

Royal College of Pharmaceutical Education & Research SayneKhurd, Malegaon, Dist. Nashik [423203] Maharashtra, India.

ARTICLE INFO

Article history

Received 18/02/2020

Available online

31/03/2020

Keywords

Microspheres,
Types of Microspheres,
Method of Preparation,
Application.

ABSTRACT

Magnetic microspheres hold great promise for reaching the goal of controlled and site specific drug delivery. Magnetic microspheres as an alternative to traditional radiation methods which uses highly penetrating radiations that is absorbed throughout the body. Its use is limited by toxicity and side effects. Now days, several targeted treatment systems including magnetic field, electric field, ultrasound, temperature, UV light and mechanical force are being used in many disease treatments (e.g. cancer, nerve damage, heart and artery, anti-diabetic, eye and other medical treatments). Among them, the magnetic targeted drug delivery system is one of the most attractive and promising strategy for delivering the drug to the specified site. Magnetically controlled drug targeting is one of the various possible ways of drug targeting. This technology is based on binding establish anticancer drug with ferrofluid that concentrate the drug in the area of interest (tumor site) by means of magnetic fields. There has been keen interest in the development of a magnetically target drug delivery system. These drug delivery systems aim to deliver the drug at a rate directed by the needs of the body during the period of treatment, and target the activity entity to the site of action. Magnetic microspheres were developed to overcome. **CONCLUSION:** Magnetism seems to be a common function of opening a new vista of a multi-barrier of multi-step drug delivery. Their main advantage is the targeting of drug using an external magnet, which can be accomplished very easily. They are relatively young drug delivery systems, having received attention from the early 1990s. In the early days of twentieth century, Paul Ehrlich envisioned his MAGIC BULLET CONCEPT-the idea that drugs reach the right site in the body, at the right time, at right concentration.

Corresponding author

Kaveri Wagh

Assistant professor,
Department of Pharmaceutics,
Royal College of Pharmaceutical Education & Research SayneKhurd,
Malegaon, Dist. Nashik [423203]
Maharashtra, India.

Please cite this article in press as **Kaveri Wagh et al. Microspheres: Review. Indo American Journal of Pharmaceutical Research.2020:10(03).**

Copy right © 2020 This is an Open Access article distributed under the terms of the Indo American journal of Pharmaceutical Research, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Oral route drug administration is by far the most preferable route for taking medications. However, their short circulating half life and restricted absorption via a defined segment of intestine limits the therapeutic potential of many drugs. Such a pharmacokinetic limitation leads in many cases to frequent dosing of medication to achieve therapeutic effect. Rational approach to enhance bioavailability and improve pharmacokinetic and pharmacodynamics profile is to release the drug in a controlled manner and site specific manner. Microspheres are small spherical particles, with diameters 1 μm to 1000 μm . They are spherical free flowing particles consisting of proteins or synthetic polymers which are biodegradable in nature. There are two types of microspheres; microcapsules and micromatrices, which are described as, Microcapsules are those in which entrapped substance is distinctly surrounded by distinct capsule wall. and micromatrices in which entrapped substance is dispersed throughout the matrix. Microspheres are sometimes referred to as microparticles. Microspheres can be manufactured from various natural and synthetic materials.

Microspheres play an important role to improve bioavailability of conventional drugs and minimizing side effects. Ideal characteristics of microspheres: [5,6] □ The ability to incorporate reasonably high concentrations of the drug. □ Stability of the preparation after synthesis with a clinically acceptable shelf life. □ Controlled particle size and dispersability in aqueous vehicles for injection. □ Release of active reagent with a good control over a wide time scale. □ Biocompatibility with a controllable biodegradability. □ Susceptibility to chemical modification. Advantages of microspheres: [6] 1. Particle size reduction for enhancing solubility of the poorly soluble drug. 2. provide constant and prolonged therapeutic effect. 3. provide constant drug concentration in blood there by increasing patient compliance, 4. Decrease dose and toxicity. 5. Protect the drug from enzymatic and photolytic cleavage hence found to be best for drug delivery of protein. 6. Reduce the dosing frequency and thereby improve the patient compliance 7. Better drug utilization will improve the bioavailability and reduce the incidence or intensity of adverse effects. 8. Microsphere morphology allows a controllable variability in degradation and drug release. 9. Convert liquid to solid form & to mask the bitter taste. 10. Protects the GIT from irritant effects of the drug. 11. Biodegradable microspheres have the advantage over large polymer implants in that they do not require surgical procedures for implantation and removal. 12. Controlled release delivery biodegradable microspheres are used to control drug release rates thereby decreasing toxic side effects, and eliminating the inconvenience of repeated injections. Limitation: [5] Some of the disadvantages were found to be as follows 1. The costs of the materials and processing of the controlled release preparation, are substantially higher than those of standard formulations. 2. The fate of polymer matrix and its effect on the environment. 3. The fate of polymer additives such as plasticizers, stabilizers, antioxidants and fillers. 4. Reproducibility is less. 5. Process conditions like change in temperature, pH, solvent addition, and evaporation/agitation may influence the stability of core particles to be encapsulated. 6. The environmental impact of the degradation products of the polymer matrix produced in response to heat, hydrolysis, oxidation, solar radiation or biological agents. TYPES OF MICROSPHERES: 1. Bioadhesive microspheres 2. Magnetic microspheres 3. Floating microspheres 4. Radioactive microspheres 5. Polymeric microspheres i)Biodegradable polymeric microspheres ii)Synthetic polymeric microspheres 1. Bioadhesive microspheres: [7,8] Adhesion can be defined as sticking of drug to the membrane by using the sticking property of the water soluble polymers. Adhesion of drug delivery device to the mucosal membrane such as buccal, ocular, rectal, nasal etc. can be termed as bio adhesion. These kinds of microspheres exhibit a prolonged residence time at the site of application and causes intimate contact with the absorption site and produces better therapeutic action.

2. Magnetic microspheres: [9,10] This kind of delivery system is very much important which localises the drug to the disease site. In this larger amount of freely circulating drug can be replaced by smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic responses to a magnetic field from incorporated materials that are used for magnetic microspheres are chitosan, dextran etc. The different types of a.Therapeutic magnetic microspheres used to deliver chemotherapeutic agent to liver tumour. Drugs like proteins and peptides can also be targeted through this system. b.Diagnostic microspheres, used for imaging liver metastases and also can be used to distinguish bowel loops from other abdominal structures by forming nano size particles supramagnetic iron oxides. 3. Floating microspheres: [11,12,13] In floating types the bulk density is less than the gastric fluid and so remains buoyant in stomach without affecting gastric emptying rate. The drug is released slowly at the desired rate, and the system is found to be floating on gastric content and increases gastric residence and increases fluctuation in plasma concentration. Moreover it also reduces chances of dose dumping. It produces prolonged therapeutic effect and therefore reduces dosing frequencies. Drug (ketoprofen) is given in the form of floating microspheres. 4. Radioactive microspheres: [3,14] Radio embolization therapy microspheres sized 10-30 nm are of larger than the diameter of the capillaries and gets trapped in first capillary bed when they come across. They are injected in the arteries that leads them to tumour of interest so all these conditions radioactive microspheres deliver high radiation dose to the targeted areas without damaging the normal surrounding tissues. It differs from drug delivery system, as radio activity is not released from microspheres but acts from within a radioisotope typical distance and the different kinds of radioactive microspheres are α emitters, β emitters, γ emitters. 5. Polymeric microspheres: [14] The different types of polymeric microspheres can be classified as follows and they are biodegradable polymeric microspheres and Synthetic polymeric microspheres. i) Biodegradable polymeric microspheres: [15] Natural polymers such as starch are used with the concept that they are biodegradable, biocompatible, and also bio adhesive in nature. Biodegradable polymers prolongs the residence time when contact with mucous membrane due to its high degree of swelling property with aqueous medium, results gel formation. The rate and extent of drug release is controlled by concentration of polymer and the release pattern in a sustained manner. The main drawback is, in clinical use drug loading efficiency of biodegradable microspheres is complex and is difficult to control the drug release. However they provide wide range of application in microsphere based treatment. ii) Synthetic polymeric microspheres: [4,16] Synthetic polymeric microspheres are widely used in clinical application, moreover that also used as bulking agent, fillers, embolic particles, drug delivery vehicles etc. and proved to be safe and biocompatible but the main disadvantage of these kind of microspheres, are tend to migrate away from injection site and lead to potential risk, embolism and further organ damage.

METHOD OF PREPARATION:

1. Spray Drying
2. Solvent Evaporation
3. Single emulsion technique
4. Double emulsion technique
5. Phase separation coacervation technique
6. Spray drying and spray congealing
7. Solvent extraction
8. Quasi emulsion solvent diffusion:

Spray Drying:

In Spray Drying technique, the polymer is first dissolved in a suitable volatile organic solvent such as dichloromethane, acetone, etc. The drug in the solid form is then dispersed in the polymer solution with high-speed homogenization. This dispersion is then atomized in a stream of hot air. The atomization leads to the formation of the small droplets or the fine mist from which the solvent evaporates instantaneously leading to the formation of the microspheres in a size range 1-100 μ m. Micro particles are separated from the hot air by means of the cyclone separator while the trace of solvent is removed by vacuum drying. One of the major advantages of this process is feasibility of operation under aseptic conditions.

Solvent Evaporation:

[14,17] This process is carried out in a liquid manufacturing vehicle phase. The microcapsule coating is dispersed in a volatile solvent which is immiscible with the liquid manufacturing vehicle phase. A core material to be microencapsulated is dissolved or dispersed in the coating polymer solution. With agitation the core material mixture is dispersed in the liquid manufacturing vehicle phase to obtain the appropriate size microcapsule. The mixture is then heated if necessary to evaporate the solvent for the polymer of the core material is dispersed in the polymer solution, polymer shrinks around the core. If the core material is dissolved in the coating polymer solution, matrix – type microcapsules are formed. The core materials may be either water soluble or water insoluble materials. Solvent evaporation involves the formation of an emulsion between polymer solution and an immiscible continuous phase whether aqueous (o/w) or non-aqueous.

Single emulsion technique:

[2] The micro particulate carriers of natural polymers i.e. those of proteins and carbohydrates are prepared by single emulsion technique. The natural polymers are dissolved or dispersed in aqueous medium followed by dispersion in non-aqueous medium like oil. In the next step, the cross linking of the dispersed globule is carried out. The cross linking can be achieved either by means of heat or by using the chemical cross linkers. The chemical cross linking agents used are glutaraldehyde, formaldehyde, acid chloride etc. Heat denaturation is not suitable for thermolabile substances. Chemical cross linking suffers the disadvantage of excessive exposure of active ingredient to chemicals if added at the time of preparation and then subjected to centrifugation, washing, separation. The nature of the surfactants used to stabilize the emulsion phases can greatly influence the size, size distribution, surface morphology, loading, drug release, and bio performance of the final multiparticulate product.

Double emulsion technique:

[2] Double emulsion method of microspheres preparation involves the formation of the multiple emulsions or the double emulsion of type w/o/w and is best suited for water soluble drugs, peptides, proteins and the vaccines. This method can be used with both the natural as well as synthetic polymers. The aqueous protein solution is dispersed in a lipophilic organic continuous phase. This protein solution may contain the active constituents. The continuous phase is generally consisted of the polymer solution that eventually encapsulates the protein contained in dispersed aqueous phase. The primary emulsion is subjected then to the homogenization or the sonication before addition to the aqueous solution of the poly vinyl alcohol (PVA). This results in the formation of a double emulsion. The emulsion is then subjected to solvent removal either by solvent evaporation or by solvent extraction. A number of hydrophilic drugs like luteinizing hormone releasing hormone (LH-RH) agonist, vaccines, proteins/peptides and conventional molecules are successfully incorporated into the microspheres using the method of double emulsion solvent evaporation/ extraction.

Phase separation coacervation technique:

[18,19] This process is based on the principle of decreasing the solubility of the polymer in organic phase to affect the formation of polymer rich phase called the coacervates. In this method, the drug particles are dispersed in a solution of the polymer and an incompatible polymer is added to the system which makes first polymer to phase separate and engulf the drug particles. Addition of non-solvent results in the solidification of polymer. Poly lactic acid (PLA) microspheres have been prepared by this method by using butadiene as incompatible polymer. The process variables are very important since the rate of achieving the coacervates determines the distribution of the polymer film, the particle size and agglomeration of the formed particles. The agglomeration must be avoided by stirring the suspension using a suitable speed stirrer since as the process of microspheres formation begins the formed polymerize globules start to stick and form the agglomerates. Therefore the process variables are critical as they control the kinetic of the formed particles since there is no defined state of equilibrium attainment.

Spray drying and spray congealing:

[18,19] These methods are based on the drying of the mist of the polymer and drug in the air. Depending upon the removal of the solvent or cooling of the solution, the two processes are named spray drying and spray congealing respectively. The polymer is first dissolved in a suitable volatile organic solvent such as dichloromethane, acetone, etc. The drug in the solid form is then dispersed in the polymer solution under high speed homogenization. This dispersion is then atomized in a stream of hot air. The atomization leads to the formation of the small droplets or the fine mist from which the solvent evaporates instantaneously leading the formation of the microspheres in a size range 1-100 μm . Microparticles are separated from the hot air by means of the cyclone separator while the traces of solvent are removed by vacuum drying. One of the major advantages of the process is feasibility of operation under aseptic conditions. The spray drying process is used to encapsulate various penicillins. Thiamine mononitrate and sulphathiazole are encapsulated in a mixture of mono- and diglycerides of stearic acid and palmitic acid using spray congealing. Very rapid solvent evaporation, however leads to the formation of porous microparticles.

Solvent extraction:

[2,18,19] Solvent evaporation method is used for manufacturing of microparticles, involves removal of the organic phase by extraction of the or non aqueous solvent. This method involves water miscible organic solvents as isopropanol. Organic phase can be removed by extraction with water. This process decreases the hardening time for the microspheres. One variation of the process involves direct incorporation of the drug or protein to polymer organic solution. Rate of solvent removal by extraction method depends on the temperature of water, ratio of emulsion volume to the water and solubility profile of polymer. 8. Quasi emulsion solvent diffusion:[18,19] A novel quasi-emulsion solvent diffusion method to manufacture the controlled release microspheres of drugs with acrylic polymers has been reported in the literature. Microspheres can be manufactured by a quasi emulsion solvent diffusion method using an external phase containing distilled water and polyvinyl alcohol. The internal phase consists of drug, ethanol and polymer. The concentration of polymer is in order to enhance plasticity. At first, the internal phase is manufactured at 60°C and then added to the external phase at room temperature. After emulsification process, the mixture is continuously stirred for 2 hours. Then the mixture can be filtered to separate the microspheres. The product is then washed and dried by vacuum oven at 40°C for a day. Polymerization techniques: [2,14,21,22] The polymerization techniques conventionally used for preparing the microspheres are mainly classified as: I. Normal polymerization II. Interfacial polymerization. Both are carried out in liquid phase. I. Normal polymerization: It is carried out by using different techniques as bulk, suspension, precipitation, emulsion and micellar polymerization methods. In bulk, a monomer or a combination of monomers along with the initiator or catalyst is usually heated to initiate polymerization. Polymer so obtained may be moulded as microspheres. Drug loading may be done during the polymerization process. Suspension polymerization also referred as bead or pearl polymerization. It is carried out by heating the monomer or composition of monomers as droplets dispersion in a continuous aqueous phase. Droplets may also contain an initiator and other additives. Emulsion polymerization deviates from suspension polymerization as due to the presence initiator in the aqueous phase, which afterwards diffuses to the surface of micelles. Bulk polymerization has merits of formation of pure polymers. II. Interfacial polymerization: This involves the reaction of various monomers at the interface between the two immiscible liquids to form a film of polymer that essentially envelops the dispersed phase.

Microspheres used usually are polymers. They are classified into two types: 1. Natural polymers 2. Synthetic Polymers 1. Natural polymers obtained from different sources like carbohydrates proteins and chemically modified Carbohydrates Carbohydrates: Agarose, Carrageenan, Chitosan, Starch Proteins: Albumin, Collagen and Gelatin Chemically modified carbohydrates: Poly dextran,

Poly starch. 2. Synthetic polymers are divided into two types. Biodegradable polymers E.g. Lactides, Glycolides & their copolymers, Poly anhydrides, Poly alkyl cyano acrylates Non-biodegradable polymers E.g. Poly methyl methacrylate (PMMA), Glycidyl methacrylate, Acrolein, Epoxy polymers.

EVALUATION OF MICROSPHERES:

Particle size and shape The most widely used procedures to visualize microparticles are conventional light microscopy (LM) and scanning electron microscopy (SEM). 2. Electron spectroscopy for chemical analysis: The surface chemistry of the microspheres can be determined using the electron spectroscopy for chemical analysis (ESCA). 3. Density determination: The density of the microspheres can be measured by using a multi volume pycnometer. 4. Isoelectric point: The micro electrophoresis is used to measure the electrophoretic mobility of microspheres from which the isoelectric point can be determined. 5. Angle of contact: The angle of contact is measured to determine the wetting property of a micro particulate carrier. 6. In vitro methods: Release studies for different type of microspheres are carried out by using different suitable dissolution media, mostly by rotating paddle apparatus (USP / BP). 7. Drug entrapment efficiency: Drug entrapment efficiency can be calculated using following equation, % Entrapment = Actual content/Theoretical content x 100. 8. Swelling index : The swelling index of the microsphere was calculated by using the formula, Swelling index= (mass of swollen microspheres - mass of dry microspheres/mass of dried microspheres) 100.

Electron spectroscopy for chemical analysis: The surface chemistry of the microspheres can be determined using the electron spectroscopy for chemical analysis (ESCA). 3. Density determination: The density of the microspheres can be measured by using a multi volume pycnometer. 4. Isoelectric point: The micro electrophoresis is used to measure the electrophoretic mobility of microspheres from which the isoelectric point can be determined. 5. Angle of contact: The angle of contact is measured to determine the wetting property of a micro particulate carrier. 6.

In vitro methods: Release studies for different type of microspheres are carried out by using different suitable dissolution media, mostly by rotating paddle apparatus (USP / BP). 7. Drug entrapment efficiency: Drug entrapment efficiency can be calculated using following equation, % Entrapment = Actual content/Theoretical content x 100. 8. Swelling index : The swelling index of the microsphere was calculated by using the formula, Swelling index= (mass of swollen microspheres - mass of dry microspheres/mass of dried microspheres) 100.

APPLICATION OF MICROSPHERES IN PHARMACEUTICAL INDUSTRY: 1. Ophthalmic Drug Delivery 2. Oral drug delivery 3. Gene delivery 4. Nasal drug delivery 5. Intratumoral and local drug delivery 6. Buccal drug delivery 7. Gastrointestinal drug delivery 8. Transdermal drug delivery 9. Colonic drug delivery 10. Vaginal drug delivery 11. Targeting by using microparticulate carriers

REFERENCES

1. Singh R. Vol. 1. New Delhi: Universal Law Publishing Co. Pvt. Ltd; 2004. Law relating to intellectual property (A complete comprehensive material on intellectual property covering acts, rules, conventions, treaties, agreements, case-Law and much more).
2. New Delhi: Department of Science and Technology (DST), Government of India; 2002. Anonymous. Research and development statistics
3. New Delhi: Department of Scientific and Industrial Research, Government of India; 2002. Anonymous. Research and development in industry: An overview.
4. Bainbridge DI. New York: Longman; 2002. Intellectual property.
5. New Delhi: Universal Law Publishing Co. Ltd; 2004. Anonymous. The Design Act. 2000 along with Design Rules 2001.
6. New Delhi: Commercial Law Publisher (India) Pvt. Ltd; 2004. Anonymous. The Trademarks Act 1999 along with trade Marks Rules 2002.
7. New Delhi: Commercial Law Publisher (India) Pvt. Ltd; 2005. Anonymous. The Copyright Act 1957 as amended up to 1999 along with Copyright Rules 1958 and International Copyright Order 1999.
8. New Delhi: Universal Law Publishing Co. Ltd; 2004. Anonymous. The Geographical Indications of Goods (registration and protection) Act, 1999 along with Geographical Indications of Goods (registration and protection) Rules 2002. []
9. New Delhi: Commercial Law Publisher (India) Private Ltd; 2005. Anonymous. The Patents Act, 1970 as amended by Patents (amendment) Act 2005. []
10. Michaels A. 2nd ed. London: Sweet and Maxwell; 1996. A practical guide to Trade Mark Law.
11. Watal J. London: Kluwer Law International; 2001. Intellectual property rights in the WTO and developing countries.
12. Abbott F, Cottier T, Gurry F. London: Kluwer Law International; 1999. The international intellectual property system: Commentary and materials. Part I.
13. Beier FK, Schricker G. Munich: Copyright and Competition Law; 1996. IIC studies: Studies in industrial property and copyright law, from GATT to TRIPS - the agreement on trade related aspects of intellectual property rights. Max Planck Institute for Foreign and International Patent.
14. New York: WIPO Publication; 2001. Anonymous. WIPO intellectual property handbook. policy, law and use.
15. Gutterman AS, Anderson BJ. London: Kluwer Law International; 1997. Intellectual property in global markets: A guide for foreign lawyers and managers.
16. Bently L, Sherman B. Oxford: Oxford University Press; 2001. Intellectual property law.
17. Angell M. The Pharmaceutical Industry. To Whom Is It Accountable? N Engl J Med. 2000;342:1902-4.
18. Lexchin J. Intellectual property rights and the Canadian pharmaceutical marketplace: Where do we go from here? Int J Health Serv. 2005;35:237-56.
19. Mrudula BS, Durgadevi NK, Madhavi BR, Tejeswi B, Durga PV. Intellectual property rights pinpoint at IPR spotlights coveted R and D. Drug Inv Today. 2009;2:197-201.
20. Glasgow LJ. Stretching the limits of intellectual property rights: Has the pharmaceutical industry gone too far? IDEA J Law Technol. 2001;41:227-58.
21. Gottlieb S. Drug firms use legal loopholes to safeguard brand names. BMJ. 2000;321:320.
22. Kartal M. Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytother Res. 2007;21:113-9.
23. Subbaram NR. Hyderabad: Pharma Books Syndicate; 2003. What everyone should know about patents Shukla S. Patents: An Introduction. Indian Pharm. 2004;3:14-7.
24. Chaudhuri, S., Goldberg, P., Jia, P. (2006). Estimating the effects of global patent protection in pharmaceuticals: A case study of quinolones in India. American Economic Review, 96(5), 1477-1514.
25. Commission on Intellectual Property Rights (2002). Integrating intellectual property rights and development policy. Report of the Commission on Intellectual Property Rights, Professor John Barton (Stanford University), Commission Chair.
26. Duggan, M., Garthwaite, C., Goyal, A. (2016). The market impacts of pharmaceutical product patents in developing countries: Evidence from India. American Economic Review, 106(1), 99-135.
27. Lerner, J. (2002). 150 years of patent protection. American Economic Review Papers and Proceedings, 92(2), 221-225.
28. Lo, S.T. (2005). Strengthening intellectual property rights: Experience from the 1986 Taiwanese patent reforms. Working Paper.
29. Maskus, K.E. (2000). Intellectual property rights in the global economy. Washington, DC: Institute for International Economics.

30. McCalman, P. (2001). Reaping what you sow: An empirical analysis of international patent harmonization. *Journal of International Economics*, 55(1), 161–186.
31. McKendrick, D., Doner, R., Haggard, S. (2000). *From Silicon Valley to Singapore: Location and competitive advantage in the hard disk drive industry*. Stanford, CA: Stanford University Press.
32. Moser, P. (2013). Patents and innovation—Evidence from economic history. *Journal of Economic Perspectives*, 27(1), 23–44.
33. Okimoto, D.I., Rohlen, T.P. (1988). *Inside the Japanese system: Readings on contemporary society and political economy*. Stanford, CA: Stanford University Press.
34. McKendrick, D., Doner, R., Haggard, S. (2000). *From Silicon Valley to Singapore: Location and competitive advantage in the hard disk drive industry*. Stanford, CA: Stanford University Press.
35. Moser, P. (2013). Patents and innovation—Evidence from economic history. *Journal of Economic Perspectives*, 27(1), 23–44.
36. Okimoto, D.I., Rohlen, T.P. (1988). *Inside the Japanese system: Readings on contemporary society and political economy*. Stanford, CA: Stanford University Press.
37. Pesek, W. (2015, December 3). Life in the republic of Samsung. *Barrons Online*, Retrieved from <http://www.barrons.com/articles/life-in-the-republic-of-samsung-1449106291>
38. Poole, J. (2013). Knowledge transfers from multinational to domestic firms: Evidence from worker mobility. *Review of Economics and Statistics*, 95(2), 393–406.
39. Prestowitz, C. (1988). *Trading places: How we allowed Japan to take the lead*. New York: Basic Books.
40. Rohlen, T. (1983). *Japan's high schools*. Berkeley, CA: University of California Press.
41. Romalis, J. (2004). Factor proportions and the structure of commodity trade. *American Economic Review*, 94(1), 67–97.
42. Rosier, K., O'Connor, S., Cuevas, R. (2016). *Taiwan's economy amid political transition*. US China Economic Security and Review Commission Staff Research Report.
43. Sakakibara, M., Branstetter, L. (2001). Do stronger patents induce more innovation? Evidence from the 1988 Japanese patent law reforms. *RAND Journal of Economics*, 32(1), 77–100.
44. Vernon, R. (1966). International investment and international trade in the product cycle. *Quarterly Journal of Economics*, 80(2), 190–208.
45. Yang, C. (2008). The effects of strengthening intellectual property rights in NIEs. *Contemporary Economic Policy*, 26(2), 22–37.
46. https://shodhganga.inflibnet.ac.in/bitstream/10603/59930/13/13_conclusion%20and%20recommendations.pdf
47. https://www.google.com/search?xsrf=ACYBGNSUnieEuYijc62SiXGKKcgVBJkfKw%3A1580626849013&ei=oXM2Xpo4x77ctQ_jgY3IAQ&q=summary+of+ipr&oq=Summof+IPR&gs_l=psy-ab.3.0.0i7i30.3084.3796.4860.0.2.0.247.898.0j1j301gws-wiz.0i71j0i13.53JvxZlaoI8ssss



54878478451200209



Submit your next manuscript to **IAJPR** and take advantage of:

Convenient online manuscript submission

Access Online first

Double blind peer review policy

International recognition

No space constraints or color figure charges

Immediate publication on acceptance

Inclusion in **Scopus** and other full-text repositories

Redistributing your research freely

Submit your manuscript at: editorinchief@iajpr.com

